Navigation Links
Study shows blood markers can help choose best dose for antiangiogenic drugs
Date:10/25/2007

Scientists at Sunnybrook have new information that may help to improve the use of anti-cancer drugs designed to block the growth of new blood vessels in tumors, a process called angiogenesis that is critical to tumor growth. While these antiangiogenic drugs are effective, at present there are no reliable methods for determining whether they are working, if the right dose is used, or if a patient will benefit (or not) from treatment.

A team led by Dr. Robert Kerbel - a senior scientist in Molecular and Cellular Biology at Sunnybrook and Canada Research Chair - has just published a paper in the October issue of the Proceedings of the National Academy of Sciences which may help to answer these questions. In the clinic, patients receiving these antiangiogenic drugs have a number of blood plasma proteins that rise and fall after treatment, so it is speculated that they could be used as surrogate biomarkers to tell us about drug activity and efficacy - our studies in mice show that this is correct, says Dr. Kerbel. In the study, Kerbels team found that drug-induced molecular changes observed in mice occurred at the same doses that had the best anti-tumor effect, suggesting that monitoring these changes in patients could predict the optimal dose of drug.

Surprisingly, the team also uncovered some unexpected insight into the nature of these observations. The current hypothesis to explain these drug-induced molecular changes is that they are tumor dependent, possibly because blocking blood flow would starve tumors of oxygen, which in turn would cause tumors to produce more proteins to recruit new vessels, says John Ebos, a doctoral student in Medical Biophysics at the University of Toronto and lead author of the study. However, our study shows that the same molecular changes occur in normal mice, that have no tumors, and come from multiple organs - suggesting that these changes come mainly from the body not the disease.

The study also found that, in addition to the molecular changes observed in the clinic, there were many other proteins that were also elevated after treatment. Ironically, many of these have been shown to have angiogenesis promoting properties and Kerbels team is now investigating the possible implications of these findings. The fact that these molecular changes occur independent of the tumor and involve many proteins that are unrelated to the drug activity, could explain why they have not been useful so far as predictors of patient benefit. They could also contribute to some of the observed drug associated toxicities seen with these drugs, play a role in drug resistance, and even may explain some recent observations where tumors rapidly regrow in some patients when therapy is stopped, using antiangiogenic drugs says Dr. Kerbel, who is also a professor in the Departments of Medical Biophysics and Laboratory Medicine/Pathobiology at University of Toronto. We are testing these hypotheses now.

In the study, the research team used a class of drugs designed to block the activation of receptors (known as receptor tyrosine kinase inhibitors, or RTKIs) activated by an important regulator of angiogenesis called vascular endothelial growth factor (VEGF). The drug they used is called sunitinib which is used for the treatment of kidney cancer, and is now being evaluated for its effects on many other types of cancer. Dr. Kerbels results have led to collaborations between his team and several medical oncologists leading clinical trials at Sunnybrooks Odette Cancer Centre involving late stage kidney cancer and early stage breast cancer therapy with the aim to determine if these preclinical findings are observed in patients, and if so, how the results might be exploited in the future to improve the benefits of antiangiogenic drugs for cancer treatment. This is a major goal of the Toronto Angiogenesis Research Centre established at Sunnybrook with the support of an infrastructure grant from the Canadian Foundation for Innovation (CFI).


'/>"/>

Contact: Natalie Chung-Sayers
natalie.chung-sayers@sunnybrook.ca
416-480-4040
Sunnybrook Health Sciences Centre
Source:Eurekalert

Related medicine news :

1. Rural Canadians travel far for specialists: study
2. A new study surpasses Gene Therapy Hurdle
3. Tomato Sauce reduces Cancer Risk- Study
4. A question on study of Adult Stem Cell
5. Study on obesity and heart failure
6. National Lung Study in the process
7. Marijuana gateway theory strengthened by study of twins
8. Old theory of adaptation confirmed by new study
9. Study casts doubt on keyboard ills
10. Gene study links endometriosis, infertility
11. Study reveals how stress can make you sick
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February ... ... to correct pelvic organ prolapse with the latest techniques and the most minimally ... risk for pelvic organ prolapse, particularly after menopause. Other risk factors include surgery ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... MyDecision™ empowers employers and organizations with the tools and information to lower the ... elements to cut the cost of providing employee healthcare benefits by as much ...
(Date:2/6/2016)... ... February 06, 2016 , ... FOR ... AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference is ... 5000 perioperative nurses in attendance to study the latest evidence-based recommendations and ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: Summer ... to their footage. A LUT is a Lookup Table that contains a mathematical formula ... indicated by the table. By manipulating each pixel, LUT's can change each color range ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... NORRITON, Pa. , Feb. 8, 2016 /PRNewswire/ ... of November Research Group (NRG),s pharmacovigilance technology ... pharmacovigilance system-related consulting services and an Oracle Argus ... compliance services to Life Sciences companies. ... strengthens and expands HighPoint,s life sciences capabilities and ...
(Date:2/8/2016)... , Switzerland and PALO ALTO, Calif. , ... biological and chemical manufacturing, and Kodiak Sciences Inc., a ... treatment of retinal disease, announced today agreements for the ... Lonza will manufacture material at multiple sites, including Slough ... --> --> Retinal diseases, such ...
(Date:2/8/2016)... , Feb. 8, 2016  Avista Pharma Solutions ("Avista ... Setzer as Chief Financial Officer (CFO). Mr. Setzer is ... of experience in various roles within growing technology and ... served as the Executive Director of Finance at INC ... Raleigh, NC . Previously, Mr. Setzer served ...
Breaking Medicine Technology: